Back to Authors

Dutta, Tumpa

https://orcid.org/0000-0003-0400-209X

Mayo Clinic

Mayo Clinic

Citations 4

Glutamine-derived 2-hydroxyglutarate is associated with disease progression in plasma cell malignancies
Ramakrishnan, Vijay , Hitosugi, Taro , Ghosh, Toshi, Jevremović, Dragan , Dutta, Tumpa , Sakrikar, Dhananjay , Petterson, Xuan-Mai, Wellik, Linda, Kumar, Shaji , Jevremovic, Dragan , Gonsalves, Wilson I. , Nair, K. Sreekumaran

JCI Insight | January 10, 2018 | Volume: 3 | Issue: 1 | Pages: No page available

10.1172/jci.insight.94543 Get It

The production of the oncometabolite 2-hydroxyglutarate (2-HG) has been associated with c-MYC overexpression. c-MYC also regulates glutamine metabolism and drives progression of asymptomatic precursor plasma cell (PC) malignancies to symptomatic multiple myeloma (MM). However, the presence of 2-HG and its clinical significance in PC malignancies is unknown. By performing 13 C stable isotope resolved metabolomics (SIRM) using U[ 13 C 6 ]Glucose and U[ 13 C 5 ]Glutamine in human myeloma cell lines (HMCLs), we show that 2-HG is produced in clonal PCs and is derived predominantly from glutamine anaplerosis into the TCA cycle. Furthermore, the 13 C SIRM studies in HMCLs also demonstrate that glutamine is preferentially utilized by the TCA cycle compared with glucose. Finally, measuring the levels of 2-HG in the BM supernatant and peripheral blood plasma from patients with precursor PC malignancies such as smoldering MM (SMM) demonstrates that relatively elevated levels of 2-HG are associated with higher levels of c-MYC expression in the BM clonal PCs and with a subsequent shorter time to progression (TTP) to MM. Thus, measuring 2-HG levels in BM supernatant or peripheral blood plasma of SMM patients offers potential early identification of those patients at high risk of progression to MM, who could benefit from early therapeutic intervention.
Precision medicine of aneurysmal subarachnoid hemorrhage, vasospasm and delayed cerebral ischemia
Burrell, Christian , Avalon, Nicole E. , Siegel, Jason , Pizzi, Michael , Dutta, Tumpa , Charlesworth, M. Cristine , Freeman, William D. , Charlesworth, M. Cristine , Freeman, William D

Expert Review of Neurotherapeutics | June 17, 2016 | Volume: 16 | Issue: 11 | Pages: 1251-1262

10.1080/14737175.2016.1203257 Get It

P1–248: Identification of altered metabolic pathways in plasma and CSF in mild cognitive impairment and Alzheimer's disease using metabolomics
Persson, Xuan‐Mai, Petersen, Ronald C. , Trushina, Eugenia , Dutta, Tumpa , Mielke, Michelle M.

Alzheimer's & Dementia | October 9, 2013 | Volume: 9 | Issue: 4S_Part_6 | Pages: No page available

10.1016/j.jalz.2013.05.472 Get It

Concordance of Changes in Metabolic Pathways Based on Plasma Metabolomics and Skeletal Muscle Transcriptomics in Type 1 Diabetes
Dutta, Tumpa , Chai, High Seng, Ward, Lawrence E., Ghosh, Aditya , Persson, Xuan-Mai T., Ford, G. C., Kudva, Yogish C. , Sun, Zhifu , Asmann, Yan W. , Kocher, Jean‐Pierre , Nair, K. Sreekumaran , Sun, Zhifu , Ghosh, Aditya K

Diabetes | March 14, 2012 | Volume: 61 | Issue: 5 | Pages: 1004-1016

10.2337/db11-0874 Get It

Insulin regulates many cellular processes, but the full impact of insulin deficiency on cellular functions remains to be defined. Applying a mass spectrometry–based nontargeted metabolomics approach, we report here alterations of 330 plasma metabolites representing 33 metabolic pathways during an 8-h insulin deprivation in type 1 diabetic individuals. These pathways included those known to be affected by insulin such as glucose, amino acid and lipid metabolism, Krebs cycle, and immune responses and those hitherto unknown to be altered including prostaglandin, arachidonic acid, leukotrienes, neurotransmitters, nucleotides, and anti-inflammatory responses. A significant concordance of metabolome and skeletal muscle transcriptome–based pathways supports an assumption that plasma metabolites are chemical fingerprints of cellular events. Although insulin treatment normalized plasma glucose and many other metabolites, there were 71 metabolites and 24 pathways that differed between nondiabetes and insulin-treated type 1 diabetes. Confirmation of many known pathways altered by insulin using a single blood test offers confidence in the current approach. Future research needs to be focused on newly discovered pathways affected by insulin deficiency and systemic insulin treatment to determine whether they contribute to the high morbidity and mortality in T1D despite insulin treatment.